Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00582140
• Other study ID #: 2004-0365
• Secondary ID: CO04806DOD-A-133
• Status: Completed
• Phase: Phase 1
• Start date: March 2005
• Est. completion date: August 2008

Study information

• Verified date: July 2015
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer. In this study the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer.

Description:

The purpose of this research is to determine the safety of serial intradermal vaccinations of a DNA vaccine encoding human PAP, with GM-CSF as a vaccine adjuvant, in subjects with stage D0 prostate cancer. In addition, to determine whether PAP-specific IFNУ-secreting CD8+ T cells can be augmented in subjects with stage D0 prostate cancer by means of immunization with a plasmid DNA vaccine encoding PAP.

This is a phase I design where patients will receive the vaccine pTVG-HP with rhGM-CSF administered i.d. biweekly for 6 total doses. There will be three escalating dose cohorts. The dosing cohort considered to be the maximum tolerated dose level will be expanded up to a total of 16 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have histologic diagnosis of adenocarcinoma of the prostate

• Must have completed local therapy by surgery and/or ablative radiation therapy at least 2 months prior to entry.

• Must have clinical stage D0 disease defined by the following: In patients treated by surgery, serum PSA values must be > 2 ng/ml by two measurements at least two weeks apart. In patients treated with ablative radiation therapy, three consecutive increases in serum PSA must be documented, with at least a one month interval between values with the finalPSA > 2ng/ml.

• Prior history of a second malignancy is allowed if treated with curative intent disease free for > 5 years.

• Karnofsky performance score of > 70

Exclusion Criteria:

• No evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), or radiation therapy to >30% of the bone marrow, within 6 months of the first vaccination.

• Must not be on concurrent androgen ablative (hormonal) therapy, or must have completed this therapy at least one month prior to study entry.

• Must not have demonstrated PSA progression during any prior hormonal therapy or chemotherapy.

• Must not have known evidence of bone metastases or non-regional lymph node involvement (stage D2 disease) as determined by bone scan or CT scan. -Must not have been treated previously with another investigational anti- tumor vaccine.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Biological:
• pTVG-HP with rhGM-CSF
pTVG-HP (dose 1: 100 µg) with rhGM-CSF (200 µg); administered i.d. biweekly for 6 total doses
• pTVG-HP with rhGM-CSF
pTVG-HP (dose 2: 500 µg) with rhGM-CSF (200 µg); administered i.d. biweekly for 6 total doses
• pTVG-HP with rhGM-CSF
pTVG-HP (dose 3: 1,500 µg) with rhGM-CSF (200 µg); administered i.d. biweekly for 6 total doses

Locations

Country	Name	City	State
United States	University of Wisconsin	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (1)

Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective of this phase I study is to determine if the vaccination with serial intradermal vaccinations of a DNA-based vaccine targeting PAP, with GM-CSF is safe (the investigators will be evaluating the degree of toxicity seen)		During study treatment and for 15 year follow-up
Primary	To determine whether PAP-specific IFN?-secreting CD8+ T cells can be generated in patients with stage D0 prostate cancer by means of immunization with a plasmid DNA vaccine encoding PAP.		12 months
Secondary	Efficacy: Immune Response and PSA response		During treatment and one year follow-up

External Links

•   University of Wisconsin Carbone Cancer Center